FOCUS
Big Pharma is no longer interested in producing and promoting old niche drugs, such as those used to treat rare diseases.
Several essential old drugs have already been withdrawn from the market, leaving doctors and patients desperate for vital treatments.
The withdrawal of such drugs is a consequence of low sales and high costs to maintain the required regulatory, supply chain and pharmacovigilance activities, impacting margin contributions to the exchange.
EFISCIENS is a global niche and specialty pharmaceutical company with EU headquarters in Pieta - Malta, and representative offices in the Middle East and Asia.
EFISCIENS offers integrated marketing, distribution and logistics services and has more than 40 drug molecules.
OUR PHILOSOPHY
EFISCIENS offers original molecules, that are well known to healthcare professionals, have proven efficacy and are often the last therapeutic option available to their patients.
EFISCIENS is committed to protecting the fundamental right of patients suffering from serious deceases to have access to personalised treatment.
EFISCIENS currently focuses on six therapeutic areas:
TRANSPLANTATION - ONCOLOGY - SUPPORTIVE CARE
CARDIOLOGY - ENDOCRINOLOGY - PSYCHIATRY
The majority of patients under treatment, represent only 100 to 1500 patients by products and by country.
EFISCIENS works in close collaboration with Patients Associations, Professional Organisations, Institutions and Governmental Agencies to supply products when drugs are in short supply.
EFISCIENS respects patients' rights and conducts its business in accordance with recognised standards of ethics, compliance and integrity.
​
REVIVING THERAPIES.....
